Literature DB >> 19614820

Natural killer cell-based immunotherapy in cancer: current insights and future prospects.

T Sutlu1, E Alici.   

Abstract

As our understanding of the molecular mechanisms governing natural killer (NK) cell activity increases, their potential in cancer immunotherapy is growing increasingly prominent. This review analyses the currently available preclinical and clinical data regarding NK cell-based immunotherapeutic approaches in cancer starting from a historical background and an overview of molecular mechanisms taking part in NK cell responses. The status of NK cells in cancer patients, currently investigated clinical applications such as in vivo modulation of NK cell activity, ex vivo purification/expansion and adoptive transfer as well as future possibilities such as genetic modifications are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614820     DOI: 10.1111/j.1365-2796.2009.02121.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  66 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.

Authors:  Tolga Sutlu; Sanna Nyström; Mari Gilljam; Birgitta Stellan; Steven E Applequist; Evren Alici
Journal:  Hum Gene Ther       Date:  2012-09-10       Impact factor: 5.695

3.  Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Authors:  Melissa A Geller; David A Knorr; David A Hermanson; Lee Pribyl; Laura Bendzick; Valarie McCullar; Jeffrey S Miller; Dan S Kaufman
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

4.  hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.

Authors:  Wen Jiang; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

5.  Successful "in-flight" activation of natural killer cells during long-distance shipping.

Authors:  Scott A Koepsell; Diane M Kadidlo; Susan Fautsch; Jeffrey McCullough; Hans Klingemann; John E Wagner; Jeffrey S Miller; David H McKenna
Journal:  Transfusion       Date:  2012-05-11       Impact factor: 3.157

6.  Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells.

Authors:  Sourav Paul; Neeraja Kulkarni; Girdhari Lal
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

7.  A Listeria-derived polypeptide promotes in vivo activation of NK cells for antitumor therapy.

Authors:  Amber L Ortiz; Laurel L Lenz
Journal:  Immunohorizons       Date:  2017-06-26

Review 8.  Investigation of NK cell function and their modulation in different malignancies.

Authors:  Gordana Konjevic; Vladimir Jurisic; Viktor Jovic; Ana Vuletic; Katarina Mirjacic Martinovic; Sandra Radenkovic; Ivan Spuzic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 9.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

10.  Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Authors:  Yin Liu; Hong-Wei Wu; Michael A Sheard; Richard Sposto; Srinivas S Somanchi; Laurence J N Cooper; Dean A Lee; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2013-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.